Tirzepatide for heart failure with obesity
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study tests whether tirzepatide, a medication that helps with weight loss and blood sugar control, can improve the ability to exercise and daily function in people who have heart failure with reduced pumping strength and are overweight or obese.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have heart failure with reduced pumping function (ejection fraction of 40% or less).
- You have a body mass index (BMI) of 27 or higher and at least one related condition like high blood pressure, diabetes, or high cholesterol.
- Your heart failure medications have been stable for at least 4 weeks.
- You agree to participate and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether the medicine tirzepatide can help adults who are overweight or obese and have congenital heart disease (a heart condition present from birth) lose weight safely. The medicine may also improve heart health and metabolism. It is for people who have already tried diet and exercise for at least a year without much weight loss.
This study tests whether combining a weight-loss medication called tirzepatide (also known as Mounjaro) with a supervised exercise program helps people lose weight and improve their overall health. You'll be in the study for about four months, and you'll get support and monitoring.
This study looks at how well the medicine tirzepatide works in real life for adults who are overweight (BMI 30 or more) and have prediabetes or type 2 diabetes. It aims to see if the medicine helps control blood sugar and weight, and it's important that you have had a recent eye exam before starting.
This trial tests the weight‑loss medication tirzepatide (Mounjaro) in people who are overweight or have obesity and have stable coronary artery disease. The goal is to see if tirzepatide can reduce dangerous fatty plaque in heart arteries.
This study tests a medicine called tirzepatide to see if it helps people with overweight or obesity lose weight, whether or not they also have type 2 diabetes. Tirzepatide is given as an injection and works on hormones that control appetite.
This Phase 2 study tests whether tirzepatide can improve how your body handles fat (especially in people with overweight or obesity) and reduce fat-related “lipotoxicity.” It may help with body fat function and related health markers, but you must meet specific health and medication rules.
Hear when a new Obesity & Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.